Revance Therapeutics Inc (RVNC)

[DewDiligence]

Migraine presents a unique issue—the injection protocol for on-label Botox treatment (31 distinct injection sites) is patented by ABBV. If RVNC decides to pursue migraine, it will need to either license ABBV’s patent or devise a new injection protocol—almost certainly the latter because devising an alternative injection protocol should be pretty straightforward.

So, you’re correct that RVNC’s pursuing migraine would require one or more phase-2 trials before advancing to phase-3.